---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-040675"
form_type: "8-K"
ticker: "AMRN"
cik: "0000897448"
company_name: "AMARIN CORP PLCUK"
filed_at: "2024-04-03T23:59:59+00:00"
generated_at: "2026-06-04T03:12:54.105058+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amarin extends VAZKEPA European patent exclusivity to 2039; defends 2033 patent

## Summary
- EPO granted new VAZKEPA patent covering REDUCE-IT protocol/results, extending exclusivity to April 2039.
- Amarin successfully defended separate VAZKEPA patent (expires June 2033) against third-party opposition at EPO.
- Legacy patent exclusivity from ANCHOR study extended via SPCs until June 2035.
- Regulatory exclusivity for VAZKEPA in Europe runs until March 2031, layering with patent protections.
- CEO Patrick Holt says extended runway enhances commercial and growth potential for VAZKEPA in Europe.

## SEC filing metadata
- accession: 0000950170-24-040675
- form_type: 8-K
- ticker: AMRN
- cik: 0000897448
- company_name: AMARIN CORP PLCUK
- filed_at: 2024-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/897448/000095017024040675/0000950170-24-040675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/897448/000095017024040675/amrn-20240403.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-040675
- JSON: https://secwatch.observer/filing/0000950170-24-040675.json
- Plain text: https://secwatch.observer/filing/0000950170-24-040675.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.